The median post-transformation survival of 5 years suggests improved outcomes for transformed follicular lymphoma in the modern era.
Introduction
Historically, follicular lymphoma (FL) that transformed to diffuse large B cell lymphoma (DLBCL) portended a poor prognosis for most patients, with a median overall survival (OS) of 1-2 years. [1] [2] [3] [4] [5] The prognosis of transformed FL (tFL) presenting at the time of initial diagnosis is uncertain because most of the prior studies of histologic transformation (HT) excluded these patients. 3, [5] [6] [7] Population-based and single institution studies of FL estimate an approximate 3% annual incidence of HT 3,5-9 . However, the incidence and outcomes of tFL may be changing with modern therapies. An analysis of the National Comprehensive Cancer Network (NCCN) non-Hodgkin lymphoma (NHL) outcomes database demonstrated 2 and 5-year OS rates of 68% and 49%, respectively, among 118 patients with tFL diagnosed between 2000 and 2011. 10 Treatment of the indolent lymphoma prior to HT included regimens containing rituximab (70%) and/or anthracyclines (51%). A smaller subset was observed without treatment (19%). While the NCCN study highlights current treatment patterns, it does not address whether initial treatment approaches impact the risk of HT. Some older retrospective studies report an increased risk of transformation with either watchful waiting or less intensive chemotherapy approaches while others, including a randomized study, observed no difference. 3, 7, 9, 11, 12 For personal use only. on May 29, 2017. by guest www.bloodjournal.org From Transformed follicular lymphoma: NLCS report 4 The large, prospective National LymphoCare Study (NLCS) database of over 2700 patients, including 80% treated at non-academic sites, provides a unique opportunity to further characterize the incidence, risk factors, including the impact of initial treatment, and outcomes of patients with tFL treated with modern therapy. Additionally, we detail the outcomes for patients with transformation at the time of initial diagnosis of FL, a subset of patients previously unreported in the current era of chemoimmunotherapy.
Methods
The NLCS is a prospective, multi-center, observational study designed to collect data on disease presentation, treatment patterns, and clinical outcomes in patients with newly diagnosed FL. There were no study-prescribed evaluations, treatments, or interventions. All patients signed informed consent before participation, and the protocol was approved by each of the participating members' institutional review boards, in accordance with the Declaration of Helsinki. Patients were enrolled between 2004 and
2007.
Patients with FL diagnosed within six months of informed consent and no prior lymphoma history were eligible for enrollment. Central pathology review was not performed, but entry of World Health Organization (WHO) definitions of FL in the database was required. Grading of FL was captured, however there was no distinction For personal use only. on May 29, 2017. by guest www.bloodjournal.org From Transformed follicular lymphoma: NLCS report 5 among grade 3 (i.e. 3A versus 3B). Initial data collection included demographics, clinical data (stage, performance status, number of nodal and extranodal sites), and routine labs. Serial treatment strategies, response to treatment, and events including transformation, relapse, and death were collected quarterly. For clinical trial participants (6% of study population), details of the investigational treatments were not collected, though treatment responses were captured. Patients were followed from enrollment through June 2014 or until death, withdrawal of consent, or lost to follow up. Additional study details were described previously. 13 Patients were categorized as transformed (suspected or confirmed) by site investigators. Guidelines to define HT were not provided. No central review of pathology or pathology reports was performed. Response was collected quarterly on electronic case report forms and HT was queried if progressive disease was noted. Forms included the options "no", "suspected", and "confirmed" HT, with confirmed cases requiring date of pathologic transformation. Suspected and confirmed cases were analyzed both individually and collectively. No guidelines were provided to define clinically suspected transformation. Patients with initial suspicion of transformation with subsequent biopsy confirmation were categorized as confirmed cases for the Cox models evaluating risk of confirmed transformation. HT was more clearly defined for the group of patients with evidence of transformation at the time of diagnosis, which consisted of patients with FL and diffuse large B cell lymphoma in the same biopsy specimen. The baseline evaluation worksheets captured the FL grade, as well as any additional histology. Patients who presented at diagnosis with evidence of FL and DLBCL in the same tissue specimen were excluded from the analyses of HT following diagnosis and analyzed separately under the category "transformation at initial diagnosis". The initial treatment worksheet included "watch and wait" and various treatment categories (e.g. single agent rituximab, single agent chemotherapy, and combined chemotherapy with or without rituximab). The quarterly update worksheets collected treatment initiation or subsequent treatment details. The observation and treatment cohorts were categorized based on the intended approach of the investigator at the time of study enrollment. A pre-specified duration of watchful waiting was not required for the observation category. 
Results

Transformation Rates
The study enrolled patients from March 2004 -March 2007 at 265 sites in the United States. 13 Of the 2734 evaluable patients, 2652 had FL as the sole histology and no progression prior to initial treatment strategy. Forty-seven patients with evidence of transformation at initial diagnosis and 30 with FL plus an additional lymphoma histology that was not clearly DLBCL were excluded from the primary analysis. At a median follow up of 6.8 years, 379/2652 patients (14.3%) had pathologically confirmed (n = 147; 5.5%) or clinically suspected (n = 232; 8.7%) transformation. The number of assessments, including CT and PET scans, obtained at the time of confirmed or suspected transformations were similar between the groups. Of the 232 patients with For personal use only. on May 29, 2017. by guest www.bloodjournal.org From suspected transformation, 25 were subsequently confirmed. Ten of the 25 patients started a treatment between suspected and confirmed transformation, of whom 8 had confirmed transformation more than one year after suspected transformation. The median time from suspected to confirmed transformation was 4.4 months, with 9 cases confirmed within one month, 6 within 1-6 months, and 10 greater than 1 year. The overall transformation rates at 2, 4, 6, and 8 years were 6.0% (95% CI 5.1-7.0%), 10.9% (95% CI 9.6-12.23%), 15.3% (95% CI 13.7-16.8%), and 19.4% (95% CI 17.5-21.3%), respectively.
Clinical and Disease Characteristics Associated with Transformation Risk
Baseline characteristics of patients with suspected or confirmed transformation, transformation at the time of diagnosis, or no transformation are detailed in Table 1 .
Factors associated with an increased risk of suspected or confirmed transformation by multiple variable Cox regression analysis were: ECOG performance status > 1 (HR 2.12, 95% CI 1.27-3.55), extranodal sites > 1 (HR 1.39; 95%CI 1.07-1.81), elevated LDH (HR 1.57, 95% CI 1.17-2.10), and B symptoms (HR 1.35, 95% CI 1.06-1.72) at diagnosis ( Table 2 ). When restricting the analysis to confirmed cases only, similar trends were observed, with the addition of advanced stage being associated with increased risk of confirmed transformation and age 80+ associated with decreased risk of confirmed transformation possibly due to differences in assessment for these populations.
Initial Treatment Patterns and Associated Risk of Transformation
For personal use only. on May 29, 2017. by guest www.bloodjournal.org From At initial diagnosis of FL, 21% of patients were observed, 13% received rituximab alone, 48% were given rituximab in combination with chemotherapy, 5%, 3%, and 3% of patients received radiotherapy, combined modality therapy, or chemotherapy alone, 6%
were treated on clinical trials, and 1% received other treatments. Of those treated with rituximab plus chemotherapy, 50% received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), 23% received R-CVP (rituximab, cyclophosphamide, vincristine, and prednisone) and 17% received fludarabinecontaining regimens. Eighty-seven patients (16% of observation patients) in the observation arm initiated treatment within 90 days. Initial treatment approaches were analyzed with respect to time to transformation and adjusted for age, stage, ECOG performance status, B-symptoms, nodal sites, LDH, histologic grade, and hemoglobin (Table 3) . 
Observation versus early treatment
Anthracycline versus non-anthracycline regimen
Of patients initially treated, 41% (n = 859) were treated with an anthracycline containing regimen and had an overall transformation rate of 11.9% compared with 14.4% in the For personal use only. on May 29, 2017. by guest www.bloodjournal.org From 10 non-anthracycline (n = 1238) arm (HR 0.69 [95% CI 0.52 -0.91]). When restricting the comparison to R-CVP versus R-CHOP, the difference was no longer statistically significant (adjusted HR 0.94 [95% CI 0.62 -1.42]).
Rituximab versus non-rituximab chemotherapy
1284 patients received rituximab plus chemotherapy and 71 received chemotherapy alone. The overall transformation rates were 13.4% and 18.3% in the rituximab and non-rituximab chemotherapy arms, respectively (HR 0.61; CI 0.34 -1.11). The length of follow-up was similar between the two groups.
Observation versus rituximab maintenance
1138 patients (609 observation; 529 rituximab maintenance) with at least a response of stable disease to an initial rituximab-based regimen who were followed for at least 215 days after the end of induction treatment without experiencing progressive disease or starting a subsequent therapy within this timeframe were included in the analysis. The HR (additionally adjusted for front line treatment) for transformation was 0.67 (CI 0.46 -0.97) with transformation rates of 9.2% in the rituximab arm compared with 13% in the observation arm.
Survival Rates
The 5-year OS rate from diagnosis was significantly worse for patients with tFL than for patients without transformation (75%, 95% CI 70-79, versus 85%, 95% CI 83-86, Fig 1) .
The median post-transformation PFS and OS were 1.0 and 4.9 years, respectively. The post-transformation PFS and OS were not significantly different between the confirmed For personal use only. on May 29, 2017. by guest www.bloodjournal.org From and suspected cases (Fig 2) . With respect to the initial treatment approach, a difference in post-transformation OS between the observed and treated groups was not detected (HR 1.24 [95% CI 0.87-1.76]). Similarly, compared with non-anthracycline treated patients, anthracycline treatment was not associated with a significant survival difference from time of transformation (HR 0.96 [95% CI 0.68-1.37]) and rituximab plus chemotherapy versus chemotherapy was not associated with significant survival differences from time of transformation (HR 0.80 [95% CI 0.39-1.64]).
Transformation at Initial Diagnosis
Among the 2734 evaluable FL cases, 77 patients had composite histology. Forty-seven of these had documentation of FL and DLBCL. The 30 additional cases coded as FL plus a second histology, were excluded because 23 cases did not specify the other lymphoma histology, 3 cases described presence of large cells but the corresponding grade was missing, 2 had CLL/SLL, 1 had marginal zone, and 1 was described as "Tcell rich" but did not specify diffuse large cell. Baseline clinical factors for the 47 patients with tFL at initial diagnosis were similar to the entire cohort (Table 1) . A considerably higher percentage of patients with transformation at initial diagnosis were treated with R-CHOP compared to the entire cohort (66% versus 24%). The 5-year PFS from diagnosis was not different for patients with tFL at diagnosis and the cohort without evidence of transformation (66%, 95% CI 50-79%, versus 61%, 95% CI 59-63%).
Likewise, the 5 year OS for patients with tFL at diagnosis of 88% (95% CI 74-95%) was similar to patients without evidence of transformation (Fig 1) .
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Treatment Patterns of Transformed Patients
Treatment approaches following suspected or confirmed transformations were quite varied ( Table 4 ). The majority of patients received rituximab, either as a single modality (26%) or with chemotherapy (35%). Only 2% of patients underwent bone marrow transplant.
Discussion
Patient characteristics from the NLCS database are similar to that of the SEER database and therefore are likely representative of the US population. 13 The NLCS database is 4.5-to 10-times larger than all previously described tFL studies; and the number of patients with transformations is nearly twice that of the largest series. In this multi-institutional, prospective, observational study, the 5 and 8 year transformation rates were 12.8% and 19.4% which is consistent with the incidence of 9-17% at 5 years and 15-30% at 10 years observed in retrospective studies. [3] [4] [5] [6] [7] 9 The observation in other series, 10, 15 as well as our own, that transformation rates are similar in the modern era suggests that chemoimmunotherapy is not impacting the incidence of transformation.
Our median follow-up of 6.8 years limits assessment of later transformations and this study cannot address whether a plateau in the incidence of HT occurs at approximately 15 years that has been seen in prior studies. 3, 5, 7, 9 At 4 years follow-up, 8 percent of patients had either withdrawn consent or were lost to follow-up compared with 12 percent at 6.8 years. Given this attrition rate, later transformations may have been missed.
For personal use only. on May 29, 2017. by guest www.bloodjournal.org From Transformed follicular lymphoma: NLCS report 13 The gold standard for diagnosing a transformation in FL is with biopsy 16 and most of the previously published studies required pathologic confirmation of transformation. 1, 6, 7, 9, 17 The Vancouver population-based analysis identified 170 patients with transformation, including 107 confirmed by biopsy and 63 diagnosed clinically based on the presence of at least one of the following: LDH ≥ 2 times the upper limit of normal, rapid localized nodal growth, new involvement of unusual extranodal sites, new B symptoms or hypercalcemia. 3 A key finding in this study was that post-transformation survival among the two groups was similar (P = 0.2). In our series, 45% of the transformations were biopsy proven which included 25 suspected cases that were subsequently confirmed by biopsy. Criteria leading treating investigators to suspect transformation and clinical characteristics at the time of transformation were not collected which is a significant limitation of the study. Importantly, however, clinical characteristics at diagnosis and outcomes following transformation were similar between pathologically confirmed and clinically suspected HT, supporting the collective analysis of both groups. The NLCS did not perform central pathology review. Most prior retrospective studies did not examine tumor specimens to confirm histology and many required reclassification of pathology reports as patients were diagnosed before the adoption of the WHO classification.
Given the relative accuracy in diagnosing transformed DLBCL with current pathology techniques, the lack of pathology review is not likely to be a major limitation. With the exception of the subset of patients with tFL at diagnosis, patients with transformation had significantly worse OS compared to patients without transformation.
The median post-transformation OS of nearly 5 years in the NLCS is similar to recent series of tFL. 10, 15 Compared with the dismal prognosis described in historical reports, these newer studies raise the question as to whether this change reflects The NLCS highlights important patterns of care following transformation, with a surprisingly low number of patients who underwent autologous stem cell transplant (ASCT). Perhaps more remarkable is that despite these practice patterns, the outcomes look much better than the historical reports. The role of ASCT for tFL is certainly more controversial in the rituximab era, with recent studies highlighting worse outcomes in patients previously treated with rituximab compared with rituximab naïve patients. [20] [21] [22] [23] There are few studies comparing initial treatment regimens and subsequent development of tFL and even fewer that are adjusted based on known clinical risk factors associated with HT. Unfortunately, none of the studies have demonstrated consistency with regards to specific regimens that may alter the risk. Additionally, none of the studies evaluate the risk with the newest regimen of bendamustine and rituximab.
Our findings demonstrated no statistically significant difference in HT with rituximab, however the non-rituximab arm was small, reflective of the use of rituximab in the For personal use only. on May 29, 2017. by guest www.bloodjournal.org From modern era, which may prevent detecting a difference in risk. Interestingly, a decreased risk of transformation was seen in patients who received rituximab maintenance and perhaps the lower transformation rate noted in those receiving early treatment compared with observed patients relates to maintenance rituximab. As the decreased risk of transformation was not borne out when comparing patients treated with R-CHOP to R-CVP despite an overall decreased risk of HT in the anthracycline versus non-anthracycline treated patients, it may be that the anthracycline is not responsible for curbing the risk. While it is possible that anthracycline-based therapies were not observed to reduce the risk of transformation due to anthracycline administration occurring more commonly in patients with biological high-risk disease, baseline clinical risk factors were adjusted for in multiple variable Cox regression analysis. Perhaps instead, certain non-anthracycline regimens may be associated with an increased risk of transformation as has been hypothesized with purine analogs. 24, 25 Fludarabine constituted a small portion of the anthracycline and non-anthracycline containing regimens in our study so analysis of this potential scenario was not feasible.
In sum, treatment strategies cannot be recommended from this observational data and the potential role for maintenance rituximab in reducing transformation will require careful attention to final reporting of HT rates in maturing randomized trials of maintenance rituximab 26-29 .
Our study's observations are best framed in the context of recent findings from the StiL and BRIGHT trials which show no OS advantage to anthracycline-based regimens, with the caveat that follow-up is still early and the prevalence of transformation is low 30,31 . A For personal use only. on May 29, 2017. by guest www.bloodjournal.org From relevant finding from our study was the lack of a post-transformation OS difference with upfront treatment. One of the few studies that may successfully address the role of observation versus early treatment is the Ardeshna trial which demonstrated no difference in HT or OS among observed patients compared to those treated with rituximab at a median follow-up of nearly four years. 28 Long term follow up of the comparative upfront chemoimmunotherapy trials as well as the Ardeshna study 28, 30, 31 will provide important data on the risk of tFL to best inform treatment decisions. 1 Adjusted for age, stage, ECOG, B-symptoms, nodal Sites, extranodal Sites, LDH, histological grade, and hemoglobin. Rituximab maintenance comparison additionally adjusted for frontline treatment. 2 Patients with at least a response of stable disease to an initial rituximab-based regimen who were followed at least 215 days after the end of induction without experiencing progressive disease or starting a subsequent therapy within this timeframe were included in analysis.
Provision of study materials and patients:
For personal use only. on May 29, 2017. by guest www.bloodjournal.org From Abbreviation: CI, confidence interval; R-CVP, rituximab, cyclophosphamide, vincristine, prednisone; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.
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